Cipher Pharmaceuticals gets to cumulative product sales milestone for Lipofen Cipher Pharmaceuticals Inc user reviews . today announced that it reached a cumulative sales milestone for Lipofen, the Company’s fenofibrate item. Achieving this focus on triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher’s U.S. Marketing and distribution partner, which will be reflected in Cipher’s revenue for the next quarter of fiscal 2010. Kowa proceeds to do a fantastic job with the promotion of Lipofen, having grown prescriptions in recent quarters solidly, said Larry Andrews, CEO and President of Cipher. This milestone additional strengthens our budget to aid our growth. .
– Net loss narrowed to $0.5 million, or $0.02 per talk about, compared with a lack of $0.8 million, or $0.03 per share, in Q1 2009. – Reached enrolment mid-stage of CIP-ISOTRETINOIN Stage III security trial. – Received favourable summary judgement movement for CIP-TRAMADOL ER, lifting 30-month stay of approval. – New Drug Submission for CIP-TRAMADOL ER accepted for review by Wellness Canada. – Strong stability sheet at one fourth end with cash of $9.1 million and no debt, weighed against cash of $9.at December 31 0 million, 2009. ‘Lipofen prescriptions have grown solidly in latest quarters with the improved promotion behind the product, which drove a solid year-over-year upsurge in our income and allowed us to narrow our operating reduction,’ said Larry Andrews, President and CEO of Cipher.